Sansoro Health is one of several health IT startups that wants to significantly improve interoperability in healthcare. As Sansoro Cofounder and CEO Jeremy Pierotti sees it, interoperability isn’t just a technology problem. It’s also a business problem. This week the company raised $5.2 million in a Series A round led by Bain Capital Ventures. Pierotti talked about the company’s plans for the funding in a phone interview with MedCity News.
Sansoro’s Emissary application is designed to help hospitals transmit data from electronic records with application programming interfaces or APIs, to support interoperability.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
Pierotti said the new funding will be used to bolster the company’s sales and marketing team. It would also be allocated to product development. He expects staff numbers to double from the current level of 16 to roughly 35 over the next 12 months.
Asked what distinguished the company’s approach from other businesses in this space, Pierotti answered this way.
“We don’t rely on legacy data exchange in healthcare…We’re building a robust, reusable messaging framework. We are building a toolset that software developers use every day in every industry”
Acknowledging his business competes with Redox Engine, Pierotti said his business great respect for Redox.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
“We happen to think our technology is more scalable,” he said.
Pierotti said the company wanted to work with Bain Capital Ventures because the investor understood Sansoro’s value proposition. “They understand healthcare technology and are deeply rooted in enterprise software so they know how to help innovative companies scale quickly.”
Last year, Sansoro Health closed a $1.2 million Seed round led by Healthy Ventures. Additional investment came from TreeHouse Health and angel investors. That year, it also emerged victorious from the Venture+ Forum pitch competition at HIMSS.
Photo: DrAfter123, Getty Images